Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110‐FGFR1 Rearrangement

This brief communication reports on a patient with an exceedingly rare “8p11 (eight‐p‐eleven) myeloproliferative syndrome” (EMS) with CEP110‐FGFR1 rearrangement who responded to treatment with the multi‐tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Wehrli, Marc, Oppliger Leibundgut, Elisabeth, Gattiker, Heinrich H., Manz, Markus G., Müller, Antonia M.S., Goede, Jeroen S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Brief Communications
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388377/
https://ncbi.nlm.nih.gov/pubmed/28242791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0354
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi